CARTEOLOL HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for carteolol hydrochloride and what is the scope of patent protection?
Carteolol hydrochloride
is the generic ingredient in three branded drugs marketed by Apotex Inc, Bausch And Lomb, Sandoz, Novartis, and Abbvie, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.There are three drug master file entries for carteolol hydrochloride. One supplier is listed for this compound.
Summary for CARTEOLOL HYDROCHLORIDE
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 5 |
| NDAs: | 5 |
| Drug Master File Entries: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,185 |
| What excipients (inactive ingredients) are in CARTEOLOL HYDROCHLORIDE? | CARTEOLOL HYDROCHLORIDE excipients list |
| DailyMed Link: | CARTEOLOL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CARTEOLOL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Otsuka Pharmaceutical Co., Ltd. | Phase 1 |
| Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
Pharmacology for CARTEOLOL HYDROCHLORIDE
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for CARTEOLOL HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for CARTEOLOL HYDROCHLORIDE
US Patents and Regulatory Information for CARTEOLOL HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | CARTROL | carteolol hydrochloride | TABLET;ORAL | 019204-003 | Dec 28, 1988 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Abbvie | CARTROL | carteolol hydrochloride | TABLET;ORAL | 019204-002 | Dec 28, 1988 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Abbvie | CARTROL | carteolol hydrochloride | TABLET;ORAL | 019204-001 | Dec 28, 1988 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Bausch And Lomb | CARTEOLOL HYDROCHLORIDE | carteolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 075546-001 | Jan 20, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sandoz | CARTEOLOL HYDROCHLORIDE | carteolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 075476-001 | Jan 3, 2000 | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CARTEOLOL HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | OCUPRESS | carteolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019972-001 | May 23, 1990 | ⤷ Subscribe | ⤷ Subscribe |
| Abbvie | CARTROL | carteolol hydrochloride | TABLET;ORAL | 019204-002 | Dec 28, 1988 | ⤷ Subscribe | ⤷ Subscribe |
| Abbvie | CARTROL | carteolol hydrochloride | TABLET;ORAL | 019204-003 | Dec 28, 1988 | ⤷ Subscribe | ⤷ Subscribe |
| Abbvie | CARTROL | carteolol hydrochloride | TABLET;ORAL | 019204-001 | Dec 28, 1988 | ⤷ Subscribe | ⤷ Subscribe |
| Novartis | OCUPRESS | carteolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019972-001 | May 23, 1990 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
